High Cholesterol Completed Phase 1 Trials for Alirocumab (DB09302)

Also known as: High Blood Cholesterol Level / Hypercholesterolemia / Hypercholesteremia / Hypercholesterolaemia / Congenital xanthoma / Hypercholesteraemia / Elevated cholesterol

IndicationStatusPhase
DBCOND0037835 (High Cholesterol)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02979015A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese SubjectsTreatment
NCT01448317Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy VolunteersTreatment
NCT01448239Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)Treatment
NCT01448304Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)Treatment
NCT01785329Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy SubjectsBasic Science
NCT01959971Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-CholesterolBasic Science
NCT01670734Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy SubjectsBasic Science
NCT01723735Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy SubjectsBasic Science
NCT01443650Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy SubjectsTreatment
NCT01161082Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant AtorvastatinTreatment